Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Effect of Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT01062230Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Jan 2010
- Primary completion
- Aug 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by University of Arkansas. Started Jan 2010; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01062230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01062230.